All In Biotech

Drug Trial Radar · NCT05020678

NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers

A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies

Last checked: Nov 19, 2026Latest source record: Apr 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

150

Planned (sponsor's estimate)

Start

Aug 20, 2021

Primary completion

Mar 31, 2025

Study completion Dec 2038

Sponsor

Lead sponsor
Nkarta, Inc.Industry
Sponsor type
Industry
First posted
Aug 25, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)

Conditions

  • Lymphoma, Non-Hodgkin
  • B-cell Acute Lymphoblastic Leukemia
  • Large B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Indolent Lymphoma
  • Waldenstrom Macroglobulinemia
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Aggressive Lymphoma
  • Large-cell Lymphoma

Interventions

  • NKX019Biological

    NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 × 10\^8 NK cells (6 × 10\^6/kg for patients \< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]Time frame: 30 days after last dose of NKX019
  2. Proportion of subjects experiencing dose-limiting toxicities of NKX019Time frame: 28 days from first dose of NKX019
  3. Objective response rate to NKX019 in Part 2Time frame: Primary assessment: 28 days after the first dose of NKX019 followed up to 2 years after the last dose of NKX019]

Locations

6 sites in 2 countries. Site status is shown where the registry gives one.

  • Colorado Blood Cancer Institute

    Denver, Colorado

  • The Cleveland Clinic Foundation

    Cleveland, Ohio

  • Institute of Haematology, Royal Prince Alfred Hospital

    Camperdown, New South Wales, Australia

  • St. Vincent's Hospital

    Sydney, New South Wales, Australia

  • Royal Brisbane and Woman's Hospital

    Brisbane, Queensland, Australia

  • Peter MacCallum Cancer Center

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.